CLOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Edge Mechanical Systems

Edge Mechanical Systems is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Germiphene Corporation

Germiphene Corporation is a Brantford, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Western Allergy Services

Western Allergy Services Ltd is a Victoria, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PHC Holdings

This is the website of PHC Holdings Corporation, which is a global innovator in healthcare solutions.

Sol-Millennium Medical Group

SOL-MILLENNIUM is a vertically integrated global medical supply company with locations across the globe. We are one of the worlds largest manufacturers of needles, syringes, and blood collection devices with a comprehensive line of medical supplies fo...